Table 1.
Summary of experimental paradigms and doses of PF-6142 used.
| Experiment | Acute dose (mg/kg) | Subchronic dose (mg/kg) | Figure |
|---|---|---|---|
| ACh level, rat | 10, SC | 10, SC for 5 d | 1 |
| ACh level, mouse | 10, SC | 10, SC for 5 d | 1 |
| LMA, mouse | 0.32, 1, 3.2, 10, SC | 1.78, 3.2, 10, SC | 2 |
| qEEG/PSG, rat | 1.0, 5.6, SC | 3 | |
| PPI, mouse | 1.78, SC | 4 | |
| CAR, rat | 1.78, SC | 4 | |
| RAM, rat | 0.01, 0.056, 0.178, 0.56, SC | 5 | |
| SDR, NHP | 0.0015, 0.015, 0.15, SC | 5 | |
| PPF, rat | 0.1, 0.3, 1.0, 3.0, IV, cumulative | 6 |
ACh, acetylcholine; FDG-PET, fluorodeoxyglucose positron emission tomography; IV, intravenous; NHP, nonhuman primate; PSG, polysomnography; LMA, locomotor activity; PPI, prepulse inhibition; CAR, conditioned avoidance response; PPF, paired-pulse facilitation; RAM, radial arm maze; SC, subcutaneous; SDR, spatial delayed response task.